Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term endothelial growth-factor. Found 17 abstracts

Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology. 2012 Dec;127(3):451-5.   PMCID: NIHMS342821
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecologic Oncology. 2012 Apr;125(1):136-40.   PMCID: pmc3303987
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 2012 Nov;18(21):6023-31.
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb;118(3):770-6.   PMCID: PMC3576704
Gupta S, Engstrom PF, Cohen SJ. Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer. 2011 Dec;10(4):298-309.   PMCID: NIHMS329029
Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, Golemis EA, Liu W. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene. 2011 Jun;30(23):2633-43.   PMCID: PMC164309
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. Clinical Cancer Research. 2011 Jun;17(11):3841-9.   PMCID: not NIH funded
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. ANNALS OF ONCOLOGY. 2006 Sep;17(9):1399-403.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(21):2516-24.
Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr;103(8):2929-35.
Soares R, Balogh G, Guo S, Gartner F, Russo J, Schmitt F. Evidence for the Notch signaling pathway on the role of estrogen in angiogenesis. Molecular Endocrinology. 2004 Sep;18(9):2333-43.
Bookman MA. Biological therapy of ovarian cancer: Current directions. Seminars in Oncology. 1998 Jun;25(3):381-96.
Devineni D, KleinSzanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Research. 1996 May;56(9):1983-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term endothelial growth-factor

endothelial growth-factor expression trial antitumor-activity angiogenesis breast-cancer tyrosine kinase inhibitor sunitinib bevacizumab factor receptor phase-ii paclitaxel colorectal-cancer inhibitor carcinoma tumors cisplatin combination 1st-line therapy solid tumors interferon-alpha vegf randomized-trial renal-cell cancer activation soft-tissue sarcomas grade uterus prognostic indicators bispecific monoclonal- liver metastasis IFL metaanalysis stem-cell factor cells in-vivo arterial-hypertension General & Internal Medicine chemotherapy oxaliplatin multikinase therapy squamous-cell carcinoma antibodies transport mutations Wnt signaling HEF1-colorectal cancer-tumorigenesis leiomyosarcoma solid receptor beta-subunit Trap) interferon placebo 1994 audhry a-anticancer research-v14-p2085 vessels doxorubicin Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor vascular endothelial growth factor colony-stimulating factor solitary fibrous tumor metastatic colorectal cancer pancreatic-cancer raf kinase clinical benefit soluble kit contrast-enhanced mri Phase II prostaglandin e-2 diastolic blood-pressure antiangiogenic therapy humanized monoclonal-antibody Carcinosarcoma AG-013736 pathways somatostatin tumor-necrosis-factor gemcitabine plus mixed mullerian tumors formulation gene histone high-dose bevacizumab ifosfamide malignant carcinoid-syndrome kinase mesna VEGF renal-cell carcinoma tgf-alpha single-chain fv albumin-bound disease lung-cancer hemangiopericytoma deacetylase inhibitors docetaxel transcriptional regulation plus fluorouracil activated killer-cells angiosarcoma fluorouracil Oncology oncology-group antiangiogenesis receptor-beta analogs carcinoma ascitic fluid mesylate interleukin-2 tumor chemotherapy axitinib-pharmacokinetics-solid tumours-non-small cell lung cancer 1992 audhry a-cancer research-v52-p1006 metastatic Targeted therapy metastasis Neuroendocrine tumors association 1993 audhry a-acta oncologica-v32-p107 Uterine leiomyosarcoma cancer-patients gastrointestinal stromal tumors phase-i su11248 angiogenesis inhibitor uterine cervix tyrosine kinase 1st-line treatment signal-transduction pathway differentiation colon-cancer vegf-trap myeloid-leukemia pancreatic endocrine tumors k-ras leucovorin 1995 lkman j-nature medicine-v1-p27 factor receptor expression human homolog double-blind first-line therapy beta-catenin Aflibercept (VEGF antitumor imidazotetrazines VEGFR axitinib GOG Nab-paclitaxel-Cervix cancer-Drug resistant cervix cancer c-kit liposarcoma recombinant gamma-interferon
Last updated on Friday, January 03, 2020